Empagliflozin fails to reduce HF hospitalizations, deaths after acute MI: EMPACT-MI

A study called EMPACT-MI found that empagliflozin, a drug used to treat type 2 diabetes, did not reduce the risk of heart failure hospitalizations or deaths after a heart attack. The study results suggest that empagliflozin may not be effective in improving outcomes for patients with acute myocardial infarction. This information is important for healthcare providers and patients to consider when deciding on treatment options.

Source link

error: Content is protected !!